Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett’s–associated esophageal adenocarcinoma

Details

• Alternative Title:
  Cancer Epidemiol Biomarkers Prev
• Personal Author:
  Rizk, Nabil P. ; Servais, Elliot L. ; Tang, Laura H. ; Sima, Camelia S. ; Gerdes, Hans ; Fleisher, Martin ; Rusch, Valerie W. ; Adusumilli, Prasad S.
• Description:
  Background
  
  Mesothelin is overexpressed in several malignancies and is purportedly a specific marker of malignant transformation. In this pilot study, we investigated whether tissue and serum mesothelin are potential markers of neoplastic progression in Barrett’s esophagus (BE) and in esophageal adenocarcinoma (EAC).
  
  Methods
  
  Mesothelin expression was retrospectively evaluated in normal, BE, and EAC tissue from surgically resected esophageal specimens (n = 125). In addition, soluble mesothelin-related peptide (SMRP) levels were measured in serum.
  
  Results
  
  Normal esophageal mucosa did not express mesothelin. BE tissue with high-grade dysplasia specifically expressed mesothelin, whereas BE tissue with low-grade or without dysplasia did not. Fifty-seven (46%) EAC tumors were positive for mesothelin. EAC tumors with BE expressed mesothelin more often than those without BE (58% vs 35%, P = 0.01). SMRP levels were elevated in 70% of EAC patients (mean, 0.89 nM; range, 0.03-3.77 nM), but not in patients with acid reflux and/or BE.
  
  Conclusions
  
  Mesothelin is commonly expressed in BE-associated esophageal adenocarcinoma. Based on this pilot study, a prospective study is under way to evaluate tissue and serum mesothelin are potential markers of neoplastic progression in BE and in EAC (NCT01393483).
  
  Impact
  
  Current surveillance methods in Barrett’s esophagus are invasive and neither cost-effective nor sensitive. This pilot study suggests that serum mesothelin is a marker of neoplastic transformation in BE and may provide a noninvasive method to improve identification of malignant transformation.
  
  
• Subjects:
  Adenocarcinoma Adult Aged Article Barrett Esophagus Barrett’s Esophagus Case-Control Studies Disease Progression Esophageal Cancer Esophageal Neoplasms Esophagus Female Follow-Up Studies GPI-Linked Proteins Humans Immunoenzyme Techniques Male Mesothelin Middle Aged Pilot Projects Prognosis Retrospective Studies Risk Factors Screening SMRP

  More +
• Source:
  Cancer Epidemiol Biomarkers Prev. 21(3):482-486
• Pubmed ID:
  22237988
• Pubmed Central ID:
  PMC3297720
• Document Type:
  Journal Article
• Funding:
  U54CA137788/CA/NCI NIH HHSUnited States/ ; U54 CA132378-04/CA/NCI NIH HHSUnited States/ ; U54 CA132378/CA/NCI NIH HHSUnited States/ ; U54 CA137788-02/CA/NCI NIH HHSUnited States/ ; U54 CA137788/CA/NCI NIH HHSUnited States/ ; U54 CA132378-03/CA/NCI NIH HHSUnited States/ ; PR101053/PR/OCPHP CDC HHSUnited States/ ; U54CA132378/CA/NCI NIH HHSUnited States/
• Volume:
  21
• Issue:
  3
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:b9453df135aaf058680395bdfa4d831ed3c5de1f6e1835eb1123ef9c15ade2d3
• Download URL:
  https://stacks.cdc.gov/view/cdc/33317/cdc_33317_DS1.pdf
• File Type:
  [PDF - 422.54 KB ]